Compass Pathways plans to complete FDA approval application by year-end
COMP Compass Inc
$10.79 +5.68%
View chart & analysis → 
- 1Compass Pathways plans to complete its FDA approval application by the end of the year.
- 2In the open-label extension phase of the study, 40-45% of patients treated with COMP360 showed at least a 50% reduction in depressive symptoms.
- 3In the open-label extension phase of the study, approximately 30% of patients treated with COMP360 achieved remission.
So what's the key point?
Compass Pathways aims to apply for drug approval from the US FDA by the end of the year. The application is anticipated as about 40% of patients with depression saw their symptoms decrease by more than half.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.